CA2685031A1 - Composition for treating diabetes and metabolic disorders with quercetin, myrcetin and chlorogenic acid - Google Patents

Composition for treating diabetes and metabolic disorders with quercetin, myrcetin and chlorogenic acid Download PDF

Info

Publication number
CA2685031A1
CA2685031A1 CA002685031A CA2685031A CA2685031A1 CA 2685031 A1 CA2685031 A1 CA 2685031A1 CA 002685031 A CA002685031 A CA 002685031A CA 2685031 A CA2685031 A CA 2685031A CA 2685031 A1 CA2685031 A1 CA 2685031A1
Authority
CA
Canada
Prior art keywords
composition
quercetin
myricetin
chlorogenic acid
foodstuff
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002685031A
Other languages
English (en)
French (fr)
Inventor
Milton Joseph Ahrens
Daryl Lee Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ATM METABOLICS LLLP
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39590291&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2685031(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2685031A1 publication Critical patent/CA2685031A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002685031A 2007-03-19 2008-03-11 Composition for treating diabetes and metabolic disorders with quercetin, myrcetin and chlorogenic acid Abandoned CA2685031A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89548607P 2007-03-19 2007-03-19
US60/895,486 2007-03-19
PCT/US2008/056474 WO2008115723A1 (en) 2007-03-19 2008-03-11 Composition for treating diabetes and metabolic disorders with quercetin, myrcetin and chlorogenic acid

Publications (1)

Publication Number Publication Date
CA2685031A1 true CA2685031A1 (en) 2008-09-25

Family

ID=39590291

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002685031A Abandoned CA2685031A1 (en) 2007-03-19 2008-03-11 Composition for treating diabetes and metabolic disorders with quercetin, myrcetin and chlorogenic acid

Country Status (8)

Country Link
US (2) US7943164B2 (https=)
EP (1) EP2129371B1 (https=)
JP (1) JP2010522185A (https=)
CN (1) CN101674821B (https=)
BR (1) BRPI0809047B8 (https=)
CA (1) CA2685031A1 (https=)
MX (1) MX2009009996A (https=)
WO (1) WO2008115723A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2685031A1 (en) * 2007-03-19 2008-09-25 Atm Metabolics Lllp Composition for treating diabetes and metabolic disorders with quercetin, myrcetin and chlorogenic acid
JP5524466B2 (ja) * 2008-10-31 2014-06-18 ユニテックフーズ株式会社 中性風味デザートベース
US9918489B2 (en) * 2008-12-17 2018-03-20 Mark Gorris Food-based supplement delivery system
US20100178413A1 (en) * 2008-12-17 2010-07-15 Mark Gorris Food-based Supplement Delivery System
JP2011001311A (ja) * 2009-06-19 2011-01-06 Pola Chemical Industries Inc 熱産生タンパク質発現促進剤
EP2464243A1 (en) * 2009-08-10 2012-06-20 Stokely-Van Camp, Inc. Method for suspending a flavonoid in a beverage
JP5892948B2 (ja) 2010-01-29 2016-03-23 アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ カルシウムｈｍｂを含む栄養エマルジョン
US9693577B2 (en) 2010-01-29 2017-07-04 Abbott Laboratories Method of preparing a nutritional powder comprising spray dried HMB
BR112012018174A2 (pt) 2010-01-29 2019-08-27 Abbott Lab líquidos nutricionais embalados assepticamente compreendendo hmb.
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
US8372447B2 (en) * 2010-08-03 2013-02-12 Northern Innovations And Formulations Corp. Compositions and methods for promoting weight loss and increasing energy
WO2012097064A1 (en) * 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for controlling blood glucose
WO2012114204A2 (en) 2011-02-15 2012-08-30 Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto Methods of treating mitochondrial dysfunction
WO2012168108A1 (en) * 2011-06-06 2012-12-13 Unilever Plc An edible composition
CN103620414A (zh) 2011-06-28 2014-03-05 皇家飞利浦有限公司 用于体液检查的部件
CN102772424B (zh) * 2012-06-13 2014-01-08 浙江大学 新橙皮苷在制备防治糖尿病药物中的应用
KR101396059B1 (ko) * 2012-06-25 2014-05-16 중앙대학교 산학협력단 소귀나무잎으로부터 분리된 신규 황산염 페놀성 화합물 및 이의 항산화 및 항염 용도
EP2867663B1 (en) 2012-06-29 2022-12-07 Koninklijke Philips N.V. Processing of bound and unbound magnetic particles
CN104395751B (zh) 2012-06-29 2016-10-19 皇家飞利浦有限公司 含有干扰颗粒的流体的处理
CN104471374B (zh) 2012-07-18 2019-05-21 皇家飞利浦有限公司 对具有目标成分的样本流体进行处理
WO2014083474A1 (en) 2012-11-30 2014-06-05 Koninklijke Philips N.V. Capture particle for selectively binding a target molecule
US11071767B2 (en) 2014-04-13 2021-07-27 Marmar Investment Sp. Z O.O. Dietary compositions for reducing blood glucose levels and for weight management
CN106461656B (zh) 2014-06-25 2020-03-24 皇家飞利浦有限公司 用于检测样品中的目标成分的生物传感器
EP3226882A4 (en) * 2014-12-01 2018-07-11 Cape Kingdom Nutraceuticals (Pty) Ltd. Therapeutic compositions
JP6594995B2 (ja) 2015-03-26 2019-10-23 コーニンクレッカ フィリップス エヌ ヴェ バイオセンサカートリッジの製造
CN105816473B (zh) * 2015-07-06 2018-04-10 武汉华纳联合药业有限公司 一种黄酮苷类组合物及其制剂和制法
JP2017105745A (ja) * 2015-12-02 2017-06-15 共栄化学工業株式会社 皮膚外用剤
US20180133243A1 (en) * 2016-11-16 2018-05-17 Holista Colltech Ltd Method and composition for crude formulations of fortified sugar for glycemic control
TWI743349B (zh) 2017-04-03 2021-10-21 大江生醫股份有限公司 包含植物萃取物的組成物及其於促進睪固酮分泌之用途
WO2020247961A1 (en) * 2019-06-07 2020-12-10 Advanced Delivery Labs Llc Compositions and methods for improving wellness
CN111387504A (zh) * 2020-04-15 2020-07-10 武汉森澜生物科技有限公司 一种含绿原酸和柚皮苷的活性提取物、提取方法及其用途
WO2023192259A1 (en) * 2022-03-28 2023-10-05 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synergy for increasing insulin sensitivity

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3134233B2 (ja) * 1991-07-26 2001-02-13 株式会社林原生物化学研究所 α−グリコシル ケルセチンとその製造方法並びに用途
CA2284290A1 (en) * 1997-03-20 1998-09-24 Samuel Russell Vester Nutritional supplement for cardiovascular health
US7229651B2 (en) * 1997-08-06 2007-06-12 Melaleuca, Inc. Dietary supplements containing natural ingredients
KR20000019716A (ko) * 1998-09-15 2000-04-15 박호군 바이오플라보노이드 화합물을 포함하는 혈당 강하용 조성물
US20020068704A1 (en) * 1999-04-05 2002-06-06 Ziegler Randy H. Compositions and methods for treatment of diabetes
US20020054924A1 (en) * 2000-04-13 2002-05-09 Leahy Margaret M. Novel compositions derived from cranberry and grapefruit and therapeutic uses therefor
US20030108627A1 (en) * 2001-09-25 2003-06-12 Jonathan Selzer Cranberry based dietary supplement and dental hygiene product
US20030133945A1 (en) * 2002-01-11 2003-07-17 Farley Michael Donald Natural food supplement
KR20050073611A (ko) * 2002-11-06 2005-07-14 카오카부시키가이샤 혈액 유동성 개선제
US7270837B2 (en) * 2003-11-10 2007-09-18 Rutgers, The State University Of New Jersey Anti-inflammatory cranberry flavonol extract preparations
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
WO2006024545A1 (en) 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes
US20060188590A1 (en) * 2005-01-05 2006-08-24 Mitsunori Ono Compositions for treating diabetes or obesity
US20070092454A1 (en) * 2005-10-24 2007-04-26 Colgate-Palmolive Company Oral composition containing morin
CA2685031A1 (en) * 2007-03-19 2008-09-25 Atm Metabolics Lllp Composition for treating diabetes and metabolic disorders with quercetin, myrcetin and chlorogenic acid

Also Published As

Publication number Publication date
MX2009009996A (es) 2010-01-20
US20110118345A1 (en) 2011-05-19
EP2129371A1 (en) 2009-12-09
CN101674821B (zh) 2013-06-26
US7943164B2 (en) 2011-05-17
US8198319B2 (en) 2012-06-12
JP2010522185A (ja) 2010-07-01
WO2008115723A1 (en) 2008-09-25
US20080234364A1 (en) 2008-09-25
EP2129371B1 (en) 2021-05-05
BRPI0809047A2 (pt) 2014-09-02
CN101674821A (zh) 2010-03-17
BRPI0809047B1 (pt) 2020-09-01
BRPI0809047B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
US7943164B2 (en) Composition and method for treating diabetes and metabolic disorders
RU2203050C2 (ru) Биофлавоноиды в качестве агента, снижающего уровень глюкозы в крови
US8962594B2 (en) Method of using nutritional compounds dihydroquercetin (taxifolin) and arabinogalactan in combination with dihydroquercetin (taxifolin) to reduce and control cardiometabolic risk factors associated with metabolic syndrome and hypercholesterolemia
KR100716799B1 (ko) 비만, 심혈관 질환 또는 관상동맥질환의 예방 및 치료용조성물
JP2008291002A (ja) メタボリックシンドロームの予防、改善または治療組成物
CN104869848A (zh) 用多酚增加黄烷-3-醇的生物利用度
WO2005006891A1 (en) Carbohydrate substitute
US20120252887A1 (en) Composition and method for treating diabetes and metabolic disorders
JP2010059104A (ja) キサンチンオキシダーゼ阻害剤
KR20040036111A (ko) 인삼 및 폴리페놀계 물질 또는 바이오플라보노이드계물질을 포함하는 식물의 분말 또는 추출물을 포함하는지질대사 개선 및 항비만용 식품
KR101686777B1 (ko) 감잎 추출물을 포함하는 혈액순환 장애 또는 대사성 질환의 예방 또는 치료용 약학적 조성물
JP2008500322A (ja) 腫瘍性疾患及び炎症を治療するための医薬製品
JP2009227609A (ja) 二次胆汁酸低下剤およびその利用
KR20110100882A (ko) 퀘르세틴을 유효성분으로 함유하는 지질대사 질환의 예방 또는 치료용 조성물
JP5744507B2 (ja) α−アミラーゼ阻害剤
KR100988510B1 (ko) 제 2형 당뇨의 예방용 조성물 및 이를 포함하는 건강보조 식품
JP2003095941A (ja) 糖質消化酵素阻害剤、血糖値上昇抑制剤、肥満治療予防剤、糖尿病治療予防剤、健康飲食物
KR20110100880A (ko) 퀘르세틴을 유효성분으로 함유하는 혈당 강하용 조성물
KR100708486B1 (ko) 섬유근육통증후군의 증상 개선 및 예방용 조성물
KR101397044B1 (ko) 아스테루빈의 신규 용도
JP2022038319A (ja) インターフェロン－γ産生促進剤
JP2012171936A (ja) 血圧降下剤または機能性組成物およびこれらを含む、食品組成物、特定保健用食品組成物、医薬部外品組成物、医薬組成物。
Class et al. Patent application title: METHOD OF USING NUTRITIONAL COMPOUNDS DIHYDROQUERCETIN (TAXIFOLIN) AND ARABINOGALACTAN IN COMBINATION WITH DIHYDROQUERCETIN (TAXIFOLIN) TO REDUCE AND CONTROL CARDIOMETABOLIC RISK FACTORS ASSOCIATED WITH METABOLIC SYNDROME AND HYPERCHOLESTEROLEMIA Inventors: Sergey V. Philippov (Moscow, RU) Sergey V. Philippov (Moscow, RU) Igor M. Bogorodov (Moscow, RU) Igor M. Bogorodov (Moscow, RU) Assignees: FLAVITPURE, INC.
Djazayery The role of flavonoids in cardiovascular disease: risk reduction, prevention and treatment.
KR20130106192A (ko) 피세틴 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 고 글루코즈로 유도된 염증 억제용 조성물

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130308

FZDE Discontinued

Effective date: 20160311